Last updated on June 2020

Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Advancing RMS Patients.


Brief description of study

To assess early phase safety and tolerability of converting patients from approved oral and injectable RMS DMTs to siponimod. The results of this study will guide clinically relevant decisions related to the transition from frequently used RMS DMTs to siponimod and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting patients from currently approved RMS DMT to siponimod.

Detailed Study Description

This is a 6-month, open-label, multi-center, single arm design, including 300 advancing RMS patients, evaluating overall safety and tolerability profile when acutely converting to siponimod from oral or injectable RMS DMT.

Clinical Study Identifier: NCT03623243

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.